<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-109182</identifier>
<setSpec>1134-3230</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Risk and benefits of hyperglycemia treatment in the non-critical hospitalized patient</dc:title>
<dc:description xml:lang="en">The prevalence of hyperglycemia in non-critical hospitalized patients is high, occurring in up to one third of patients not previously diagnosed with diabetes. Hyperglycemia increases hospital morbidity and mortality, the impact being greater in patients not known to be diabetics. The effect of intensive treatment of hyperglycemia in non-critical hospitalized patients is unclear, the only proven benefit is the reduction in the risk of infection. The current recommendation is to keep blood glucose levels &lt;140mg/dL, and to use the basal-bolus insulin therapy for the glycemic control during hospitalization. Although the fear of inducing hypoglycemia is one of the main causes of poor glycemic control, the evidence of its impact on hospital morbidity and mortality is very limited. Only spontaneous hypoglycemia at admission and is associated with increased hospital mortality. There is an increased risk of iatrogenic hypoglycemia at discharge, so this should be carefully monitored(AU)</dc:description>
<dc:creator>Botella Serrano, Marta</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La prevalencia de hiperglucemia en los pacientes hospitalizados no críticos es alta, presentándose hasta en un tercio de los pacientes no diagnosticados previamente de diabetes. La hiperglucemia aumenta la morbimortalidad intrahospitalaria, siendo el impacto mayor en los pacientes no diabéticos conocidos. El beneficio del tratamiento intensivo de la hiperglucemia en pacientes hospitalizados no críticos está poco establecido, el único beneficio demostrado es la disminución del riesgo de infecciones. La recomendación actual es mantener una glucemia basal &lt;140 mg/dl y utilizar la terapia bolo-basal para el control de la hiperglucemia durante el ingreso. Aunque el miedo a la hipoglucemia es una de las causas fundamentales del insuficiente control glucémico, la evidencia que tenemos de su repercusión en la morbimortalidad hospitalaria es muy limitada. La hipoglucemia al ingreso y la espontánea sí está asociada a un aumento de mortalidad intrahospitalaria. El mayor riesgo de hipoglucemia iatrogénica se produce al alta hospitalaria, por lo cual se debe planificar esta de forma adecuada(AU)</dc:description>
<dc:source>Av. diabetol;28(5): 105-109, sep.-oct. 2012.</dc:source>
<dc:identifier>ibc-109182</dc:identifier>
<dc:title xml:lang="es">Riesgos y beneficios del tratamiento de la hiperglucemia en el paciente hospitalizado no crítico</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d7181^s22012</dc:subject>
<dc:subject>^d3942^s22080</dc:subject>
<dc:subject>^d7181^s22016</dc:subject>
<dc:subject>^d7553^s22066</dc:subject>
<dc:subject>^d30047^s22066</dc:subject>
<dc:subject>^d28418</dc:subject>
<dc:subject>^d7553^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12720^s22066</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d7124^s22012</dc:subject>
<dc:subject>^d12721</dc:subject>
<dc:subject>^d7500^s22073</dc:subject>
<dc:subject>^d7501^s22073</dc:subject>
<dc:subject>^d7124^s22080</dc:subject>
<dc:subject>^d3942^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>201210</dc:date>
</metadata>
</record>
</ibecs-document>
